Moreover, SGLT2 inhibitors showed risk reduction of heart failure hospitalization in T2DM patients, suggesting that SGLT2 inhibitors play a key role in the improvement of cardiac function in diabetic cardiomyopathy [8]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.